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The calcineurin/nuclear factor of activated T-cell
(NFAT) pathway represents a crucial transducer of cel-
lular function. There is increasing evidence placing the
sarcolemmal calcium pump, or plasma membrane calci-
um/calmodulin ATPase pump (PMCA), as a potential
modulator of signal transduction pathways. We demon-
strate a novel interaction between PMCA and the calci-
um/calmodulin-dependent phosphatase, calcineurin, in
mammalian cells. The interaction domains were located
to the catalytic domain of PMCA4b and the catalytic
domain of the calcineurin A subunit. Endogenous cal-
cineurin activity, assessed by measuring the transcrip-
tional activity of its best characterized substrate, NFAT,
was significantly inhibited by 60% in the presence of
ectopic PMCA4b. This inhibition was notably reversed
by the co-expression of the PMCA4b interaction domain,
demonstrating the functional significance of this inter-
action. PMCA4b was, however, unable to confer its in-
hibitory effect in the presence of a calcium/calmodulin-
independent constitutively active mutant calcineurin A
suggesting a calcium/calmodulin-dependent mecha-
nism. The modulatory function of PMCA4b is further
supported by the observation that endogenous cal-
cineurin moves from the cytoplasm to the plasma mem-
brane when PMCA4b is overexpressed. We suggest re-
cruitment by PMCA4b of calcineurin to a low calcium
environment as a possible explanation for these find-
ings. In summary, our results offer strong evidence for a
novel functional interaction between PMCA and cal-
cineurin, suggesting a role for PMCA as a negative mod-
ulator of calcineurin-mediated signaling pathways in
mammalian cells. This study reinforces the emerging
role of PMCA as a molecular organizer and regulator of
signaling transduction pathways.
The essential role of Ca2 in signal transduction pathways is
well established (1). Critical to the coupling of Ca2 signals to
cellular responses is the serine-threonine protein phosphatase
calcineurin (Cn1; also called protein phosphatase 2B), which is
regulated by Ca2/calmodulin (2, 3). Its structure is highly
conserved from yeast to humans, and although abundant in
neural tissue, it is found widely distributed (4).
The nuclear factor of activated T-cell (NFAT) transcription
factors are the best characterized substrate of calcineurin (5).
The key effect of calcineurin activation is the dephosphoryl-
ation of this family of transcription factors in response to a
sustained increase in intracellular Ca2, leading to nuclear
translocation of NFATs and resultant activation of gene tran-
scription (6). The strong body of evidence implicating NFATs in
the development and adaptation of a varied range of cell types
underlines the importance of calcineurin function (7). The cal-
cineurin holoenzyme is a heterodimer consisting of a 58- to
64-kDa catalytic subunit, calcineurin A (CnA), and a 19-kDa
regulatory subunit, calcineurin B (CnB) (8). CnA comprises a
catalytic domain at the N-terminal region (residues 70–328) (8)
and three regulatory domains at the C terminus; the CnB
binding domain (8–10), the calmodulin binding domain (11),
and the “autoinhibitory” domain (12). In the absence of Ca2/
calmodulin, calcineurin is inactive as the autoinhibitory do-
main binds in the active site cleft (12). Ca2/calmodulin bind-
ing to the calmodulin binding domain of CnA displaces the
autoinhibitory domain ceasing the inhibition (12).
We have recently reported a role for the plasma membrane
Ca2/calmodulin ATPase pump (PMCA) as a modulator of
Ca2/calmodulin-dependent enzymes (13, 14). PMCAs are
enzymatic low capacity, high affinity systems involved in the
extrusion of Ca2 from the cell (15). Four different PMCA
isoforms, PMCA1–4, have been identified in mammals and
are encoded by four independent genes (16–21) with alterna-
tive splicing of each of the genes’ primary transcript at three
independent sites (22, 23). PMCA1 and -4 are ubiquitously
expressed, whereas PMCA2 and -3 show a more restricted
cell- and tissue-specific pattern of expression (16, 20). The
primary protein structure of PMCAs consists of 10 mem-
brane-spanning segments, two major cytosolic loops, and N
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and C cytoplasmic tails. PMCA4b has been shown to inhibit
the activity of the Ca2/calmodulin-dependent protein neu-
ronal nitric-oxide synthase (nitric-oxide synthase I) (13) and
calcium/calmodulin-dependent serine protein kinase or
CASK (14), by tethering them to low Ca2/calmodulin cellu-
lar microdomains via interaction between the C-terminal end
of PMCA4b and PDZ domains located in the partner proteins.
Recent findings in our laboratory have demonstrated the
interaction of other intracellular regions of PMCA with pro-
teins that do not contain a PDZ domain (24). This, and the
calcium/calmodulin-dependent nature of calcineurin, raised
the possibility that PMCA may regulate the activity of cal-
cineurin (a protein without PDZ-domain) through interaction
with a region other than the C terminus. In keeping with this
hypothesis, a number of calcineurin-binding proteins have
been reported to inhibit its phosphatase activity via physical
interaction with the calcineurin A catalytic subunit (25).
Here we characterize PMCA as a novel inhibitory protein of
endogenous calcineurin in mammalian cells. We show that
the physical interaction between PMCA and calcineurin is
required to inhibit calcineurin activity. This study provides
new insight into the regulation of the calcineurin/NFAT sig-
naling pathway and suggests a role for PMCA as an upstream
regulator of this pathway in the differentiation and adapta-
tion of varied tissue types.
MATERIALS AND METHODS
Cell Culture—HEK 293 cells were maintained in Dulbecco’s modified
Eagle’s medium (Life Technologies) supplemented with 10% fetal calf
serum and 1% penicillin/streptomycin.
Plasmids—pCMV-hPMCA4b contains the human PMCA4b cDNA
and was a gift from Prof. E. Strehler (Dept. of Biochemistry and Mo-
lecular Biology, Mayo Clinic, Rochester, MN).
The region encoding amino acids 2–521 of human calcineurin A was
amplified by 40 cycles of PCR (the conditions were: denaturation 94 °C
for 60 s, annealing 58 °C for 60 s, and extension 72 °C for 2 min) using
the oligonucleotides as follows: hCnA2Sense (5-CGGGATCCGAGC-
CCAAGGCAATTGATC-3) and hCnA521Anti (5-GCTCTAGAAGTG-
GTCACTGAATATTGCTGCTATTAC-3). The amplified product was di-
gested with BamHI and XbaI and cloned into the BamHI-XbaI sites of
plasmid pEF-FLAG (26) to generate plasmid pFCnA-(2–521).
The region encoding amino acids 2–397 from human calcineurin A
 was amplified from total RNA amplified from total RNA extracted
from Jurkat cells by 30 cycles of PCR (the conditions were: denatur-
ation 94 °C for 60 s, annealing 62 °C for 60 s, and extension 72 °C for
1 min for the first 10 cycles, followed by 20 cycles in the same
conditions except for the annealing temperature that was raised up to
68 °C) using the oligonucleotides hCnA397 Sense (5-AGA TCT GAG
CCC AAG GCA ATT GAT CCC-3) and hCnA397 Anti (5-TCG CGA
CCT TAT CAC TTT CCG GGC-3). The PCR product was first cloned
into pGEM-T easy vector (Promega) and the BglII-PvuII DNA frag-
ment, coding for a constitutively active deletion mutant (amino acids
2–389), was further “in-frame” subcloned into BamHI-blunt (EcoRI
plus fill-in with Klenow) digested pEF-FLAG expression vector to
generate the pFCnA-(2–389) construct.
To generate plasmid pFCnA-(2–173) a BglII-blunt (MluI plus fill-in
with Klenow) cDNA fragment from pGEM-CnA-(2–397) and encoding
the region encompassing amino acids 2–173 of human calcineurin A 
was subcloned in-frame into BamHI-blunt digested pEF-FLAG expres-
sion vector.
The region encoding amino acids 3–143 of human calcineurin  was
amplified by 35 cycles of PCR (the conditions were: denaturation 94 °C
for 30 s, annealing 56 °C for 1 min, and extension 72 °C for 1 min) using
the oligonucleotides HindhCnA3Sense (5-TCTTCCCAAgCTTgAgC-
CCAAggCAATTgATCCC-3) and BamHhCnA143Anti (5-TCTTCg-
CggATCCTCATgTTTTggggTAgAgAATTTTC-3). The regions encod-
ing amino acids 3–97 and 3–57 were amplified by 35 cycles of PCR
(the conditions were: denaturation 94 °C for 30 s, annealing 54 °C for
30 s, and extension 72 °C for 30 s) using the oligonucleotides
HindhCnA3Sense and BamHhCnA97Anti (5-TCTTCgCggATCCTC-
AATCAAAgAATTgTCCATgAATg-3) and BamHhCnA57Anti (5-TC-
TTCgCggATCCTCATTCCAgCCTTCCCTCCTTCATA-3), respectively.
The amplified products were digested with HindIII and BamHI and
cloned into the HindIII and BamHI sites of plasmid p3xFLAG-CMV7.1
(Sigma) to generate plasmids pFCnA-(3–143), pFCnA-(3–97), and
pFCnA-(3–57), respectively.
Fragments of the human PMCA4b encompassing amino acids 1–92
(N-terminal cytoplasmic), 428–658 (part of the big intracellular loop
domain between transmembrane regions 4 and 5), and 1137–1205 (C-
terminal cytoplasmic, numbering according to accession number
NM_001684) were amplified by 35 cycles of PCR (the conditions were:
denaturation 94 °C for 30 s, annealing 62 °C for 30 s, and extension
FIG. 1. Human PMCA4b and calcineurin A interact in mammalian cells. A, domain structures of FLAG-tagged full-length calcineurin
A-(2–521) and a constitutively active mutant version calcineurin A-(2–389). CNB, calcineurin B binding domain; CaM, calmodulin binding domain;
AID, autoinhibitory domain. B, human PMCA4b and full-length, or constitutively active calcineurin A, co-precipitate in mammalian HEK 293 cells.
Expression vectors encoding human PMCA4b and a FLAG-tagged version of full-length, or constitutively active calcineurin A , were co-
transfected in HEK 293 cells. Protein lysates were incubated with an anti-PMCA monoclonal antibody (5F10), or an irrelevant antibody raised
against firefly luciferase (-Luc), and the immunoprecipitated proteins were probed with the JA3 anti-PMCA4b monoclonal antibody or the M2
anti-FLAG monoclonal antibody to detect PMCA4b (WB:-PMCA) or FLAG-tagged calcineurin A (WB:-CnA), respectively. Cells transfected with
empty vector (pEF-FLAG), or left untransfected, were used as negative controls.
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72 °C for 30 s) using the oligonucleotides ECOPMCA4b1Sense (5-TC-
TTCCggAATTCATgACgAACCATCAgACCgTg-3) and BAMHPMCA-
4bAnti92 (5-TCTTCgCggATCCTCAAgTCTgggCTTTTTggggggg-3) for
region 1–92, oligonucleotides ECOPMCA4bSense428 (5-TCTTCCggA-
ATTCCgCTgTCACCTCTCACTggCCT-3) and BAMHPMCA4bAnti651
(5-TCTTCgCggATCCTCAAAgAggCTCTgTgTCATCgAA-3) for region
428–651, and oligonucleotides ECOPMCA4bSense1137 (5-TCTTCCg-
gAATTCCgCCATAgAggAggAg-3) and BAMHPMCA4bAnti1205 (5-T-
CTTCgCggATCCTCAAACTgAgTCTCTAggC-3) for region 1137–1205.
The amplified products were digested with EcoRI and BamHI and
cloned into the EcoRI and BamHI sites of plasmid p3xFLAG-CMV7.1 to
generate plasmids pF-PMCA4b-(1–92), -(438–651), and -(1137–1205).
Fragments of the human PMCA4b encoding amino acids 428–500
and 428–575 (part of the big intracellular loop between transmembrane
regions 4 and 5) were amplified by 35 cycles of PCR (the conditions
were: denaturation 94 °C for 1 min, annealing 58 °C for 1 min, and
extension 72 °C for 1 min 30 s) using the oligonucleotides ECOPMCA-
4BSense428 (5-TCTTCCggAATTCCgCTgTCACCTCTCACTggCCT-3)
and BAMHPMCA4bAnti575 (5-TCTTCgCggATCCTCACATTgACTTg-
CgCACTgAgTT-3) for region 428–575 and oligonucleotides ECOPMC-
A4BSense428 (5-TCTTCCggAATTCCgCTgTCACCTCTCACTggCCT-
3) and BAMHPMCA4bAnti500 (5-TCTTCgCggATCCTCAgACTTTgg-
gCAggAAgACATCA-3) for region 428–500. The amplified products
were digested with EcoRI and BamHI and cloned into the EcoRI and
BamHI sites of plasmid p3xFLAG-CMV7.1 to generate plasmids pF-P-
MCA4b-(428–575) and -(428–500). The fidelity of all PCR amplified
products was confirmed by sequencing.
Transient Transfections—For immunoprecipitation experiments
HEK 293 cells were plated in 100- 20-mm tissue culture dishes (4.5
106 cells/plate) the day before transfection. Transfections were per-
formed with 10 g of the relevant expression plasmid using Lipo-
fectamine 2000 reagent (Invitrogen) as previously described (24).
For Luciferase assays, HEK 293 cells were plated in 6-well tissue
culture plates (7 105 cells/well) the day before transfection. Cells were
transfected with the relevant expression vectors, which included 4 g of
expression vector and 1 g of the luciferase reporter vector pNFAT-TA-
Luc (Clontech). Lipofectamine 2000 reagent (Invitrogen) was used to
transfect the vectors according to the manufacturer’s instructions. Cells
were incubated with DNA-Lipofectamine complexes for 24 h, washed
with PBS, and then incubated overnight in 5 ml of fresh Dulbecco’s
modified Eagle’s medium-10% fetal calf serum. Where relevant, the
cells were stimulated with PMA (20 ng/ml) and the calcium ionophore
A23187 (1 M) prior to incubation. The following morning, cells extracts
were prepared, and luciferase activity was determined with a luciferase
assay system (Promega). Transfection efficiency was normalized by
co-transfection of plasmid pEF-LacZ carrying the -galactosidase gene
under the control of the EF1 promoter, and determination of -galac-
tosidase activity (27).
Immunoprecipitation—Transfected HEK 293 cells or rat neonatal
cardiomyocytes were lysed with radioimmune precipitation assay
buffer (1 PBS, 1% Igepal, 0.5% sodium deoxycholate, 0.1% SDS, 20 M
phenylmethylsulfonyl fluoride, 500 ng/ml leupeptin, 1.0 g/ml aproti-
nin, 500 ng/ml pepstatin) and protein extracts immunoprecipitated
with the corresponding antibodies as described. Immunoprecipitated
proteins were analyzed by Western blot.
Cellular Fractions—HEK 293 cells were plated in 100-  20-mm
tissue culture dishes (4.5  106 cells/plate), and transfected the follow-
ing day. Transfections were performed with 10 g of the relevant
expression plasmid using Lipofectamine 2000 reagent (Invitrogen) as
previously described (24).
Plasma membrane fractions were obtained using a previously de-
scribed method based on biotin and avidin interaction (28). Briefly, cells
were harvested after 72 h. Cells were washed with PBS twice, and 27 
106 cells resuspended in 1 ml of PBS before biotinylation with 10 mM
Sulfo-NHS-biotin (Pierce) for 30 min at room temperature. After bioti-
nylation, cells were washed three times with PBS to remove excess
biotin reagent and byproducts. Crude plasma membranes were then
prepared. The cells were collected and incubated in 1 ml of cytosolic
lysis buffer (10 mM Hepes, 10 mM NaCl, 5 mM NaHCO3, 1 mM CaCl2, 0.5
mM Mg Cl2, 1 mM phenylmethylsulfonyl fluoride, aprotinin, 5 mM
EDTA) for 5 min on ice. The cells were then homogenized and centri-
fuged at 3000  g, at 4 °C, to pellet nuclei and intact cells. To prepare
purified plasma membranes, the supernatant, containing the biotiny-
lated crude plasma membranes, was then incubated with 100 l of
avidin beads (Immunopure Immobilized Monomeric Avidin, Pierce) for
1 h at room temperature. The purified plasma membranes were sepa-
rated from the cytoplasmic fraction by centrifuging at 3000 g to pellet
the beads. The beads, containing the bound membranes, were washed
twice with 1 ml of cytosolic lysis buffer. Samples were analyzed by
Western blot.
Western Blot—Samples were boiled and resolved, under reducing con-
ditions, by SDS-PAGE (6 or 12% polyacrylamide for human PMCA4b or
FLAG-tagged calcineurin A detection, respectively). The gels were trans-
ferred onto nitrocellulose membranes and Western blot performed as
previously described (24) using a 1:1000 solution of JA3 monoclonal an-
tibody (Neomarkers) in TBS-T for PMCA4b detection, a 1:1000 solution
of anti-FLAG M2 peroxidase-conjugate monoclonal antibody (Sigma-
Aldrich) in TBS-T, for FLAG-epitope detection, a 1:1000 solution of 5F10
anti-PMCA monoclonal antibody (Abcam) in TBS-T or a 1:1000 solution of
anti-calcineurin A monoclonal antibody (BD Bioscience) in TBS-T. Where
relevant, developed films were scanned, and band densitometry was cal-
culated on a densitometer (Gene Tools, Syngene, Europe).
RESULTS
PMCA Interacts with the Catalytic Subunit of Calcineurin in
Mammalian Cells—HEK 293 cells were co-transfected with
the expression plasmids pCMV-hPMCA4b (encoding human
PMCA4b), and pFCnA-(2–521) (encoding full-length human
FIG. 2. Interaction with PMCA4b maps to the region 58–143 of
calcineurin A. A, schematic representation of FLAG-tagged C-termi-
nal deletion mutants of calcineurin A. CNB, calcineurin B binding
domain. B, expression vectors encoding human PMCA4b and FLAG-
tagged C-terminal deletion mutants of calcineurin A  encoding amino
acids 2–389, 2–173, 2–143, 2–97, or 2–57, were co-transfected in HEK
293 cells. Cells left untransfected and those transfected with the empty
vector (pEF-FLAG) were used as negative controls. Protein lysates were
incubated with the anti-PMCA monoclonal antibody (5F10). Immuno-
precipitated proteins (upper Western blots) and the expression levels of
the recombinant proteins prior to immunoprecipitation (lower Western
blots) were probed with the M2 anti-FLAG monoclonal antibody. The
arrowhead indicates the decrease in the interaction of mutant FLAG-
CnA-(3–97) (upper right hand panel) and its expression levels (lower
right hand panel), suggesting that the region 98–143 plays a major role
in the interaction. The arrow denotes the absence of interaction of
mutant FLAG-CnA-(3–57) (upper right hand panel) in the context of
equivalent expression levels (lower right hand panel). Interaction with
PMCA4b thus maps to the region 58–143 of calcineurin A.
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calcineurin A ) or pFCnA-(2–389) (encoding a constitutively
active version lacking the calmodulin-binding domain and
the autoinhibitory domain) (Fig. 1A). Protein extracts were
immunoprecipitated with the anti-PMCA antibody 5F10, and
probed by Western blot to demonstrate co-precipitation of
PMCA with FLAG-tagged calcineurin A full-length,
FLAGCnA-(2–521) (Fig. 1B, left panel) or the constitutively
active mutant, FLAGCnA-(2–389) (Fig. 1B, right panel). The
specificity and selectivity of the interactions were confirmed
by the absence of co-precipitation in cells transfected with the
pEF-FLAG empty vector (Fig. 1B, right panel) and immuno-
precipitations performed with an irrelevant antibody (anti-
Luciferase), respectively (Fig. 1B). These results thus dem-
onstrate a physical interaction between PMCA4 and
calcineurin A in mammalian cells.
The Region 58–143 of Calcineurin A Is Critical for Interac-
tion with PMCA4b—To finely map the minimal interaction
domain of calcineurin A responsible for the interaction with
PMCA, a series of FLAG-tagged C-terminal deletion mutants of
calcineurin A  were generated (Fig. 2A) and then assayed by
immunoprecipitation for their ability to interact with human
PMCA in mammalian cells.
FIG. 3. The region 501–575 of human
PMCA4b interacts with calcineurin.
A, schematic representation of FLAG-
tagged proteins containing the N-termi-
nal (amino acids 1–92) intracellular re-
gion of human PMCA4b, the region 428–
651 of its catalytic domain, and the
fragment 1137–1205 of the C-terminal in-
tracellular region. The numbers corre-
spond to human PMCA4b amino acids ac-
cording to accession number NM_001684.
B, immunoprecipitation analysis of the
interaction between calcineurin and
FLAG-tagged proteins containing the re-
gions 1–92, 428–651, or 1137–1205 of hu-
man PMCA4b. Expression vectors encod-
ing FLAG-tagged PMCA4b-(1–92), -(428–
651), or -(1137–1205) were transfected in
HEK 293 cells. Empty vector (p3xFLAG-
CMV7.1, Sigma) was used as a negative
control. Protein lysates were incubated
with commercial calcineurin (20 nM,
Sigma), and then complexes precipitated
with an anti-calcineurin monoclonal anti-
body (BD Biosciences). FLAG-tagged im-
munoprecipitated proteins were detected
by Western blot with M2 anti-FLAG per-
oxidase monoclonal antibody (upper West-
ern blots). Expression levels of the FLAG
proteins prior to immunoprecipitation
were analyzed by Western blot (lower
Western blots). The region 428–651, lo-
cated within the catalytic big intracellu-
lar loop of PMCA4b specifically interacts
with calcineurin. C, schematic represen-
tation of FLAG-tagged C-terminal dele-
tions of the region 428–651 generated to
determine the minimal region interacting
with calcineurin. D, expression vectors
encoding FLAG-tagged versions of the re-
gions 428–651, 428–575, or 428–500 of
human PMCA4b were transfected in
HEK 293 cells. Protein lysates were im-
munoprecipitated as described in Fig. 3B.
Western blots were then probed with the
M2 anti-FLAG monoclonal antibody to
detect immunoprecipitated proteins (up-
per Western blot) and expression levels
(lower Western blot). FLAG proteins con-
taining amino acids 428–651 or 428–575
of PMCA4b both co-precipitated with
calcineurin. FLAG-PMCA4b-(428–500),
however, failed to interact with cal-
cineurin, narrowing down the interaction
domain to the region 501–575 of human
PMCA4b.
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HEK 293 cells were co-transfected with pCMV-hPMCA4b
and plasmids encoding pFCnA-(2–389), pFCnA-(2–173),
pFCnA-(3–143), pFCnA-(3–97), or pFCnA-(3–57). Protein ex-
tracts were immunoprecipitated with the anti-PMCA4 mono-
clonal antibody 5F10 and probed by Western blot to demon-
strate co-precipitation of PMCA. The levels of co-precipitation
were significantly reduced when amino acids 143–98 were re-
moved, reflected by the results of mutant FLAG-CnA-(3–97)
(Fig. 2B, right upper panel). Furthermore, the removal of
amino acids 97 to 58 in pFCnA-(3–57) completely prevented
co-precipitation with PMCA (Fig. 2B, right upper panel). Im-
munoprecipitations with an irrelevant antibody (anti-Lucif-
erase) did not precipitate any protein (data not shown) demon-
strating the specificity of the interaction. Untransfected cells,
or cells transfected with the pFLAG empty vector were used as
negative controls (Fig. 2B, upper panels). Levels of the FLAG
proteins prior to immunoprecipitation were analyzed by West-
ern blot to ensure differences were not attributable to differen-
tial expression (Fig. 2B, lower panels). These results indicate
that the region 98–143 of calcineurin A is necessary for inter-
action with PMCA4b, whereas amino acids 58–97 appear to
contribute to the interaction.
The Region 501–575 of PMCA4b Is Essential for Interaction
with Calcineurin A—To identify the region of PMCA4b in-
volved in the interaction with calcineurin A, we generated
FLAG-tagged fusion proteins containing either the N terminus,
part of the catalytic domain, or the C terminus intracellular
regions of PMCA4b (Fig. 3A).
HEK 293 cells were transfected with plasmids pF-PMCA4b-
(1–92), -(428–651), or -(1137–1205). Commercially available
calcineurin was added to the protein lysates, which were then
immunoprecipitated with a monoclonal anti-calcineurin A an-
tibody, and probed by Western blot. FLAG-PMCA4b-(428–651)
strongly co-precipitated with calcineurin (Fig. 3B, upper panel).
However, no precipitation was detected when FLAG-tagged
proteins containing the N or C termini intracellular domains of
PMCA4b were used in the assay (Fig. 3B, upper panel). Cells
transfected with empty vector p3xFLAG-CMV7.1 were used as
a negative control (Fig. 3B, upper panel). The FLAG-tagged
PMCA4b proteins were expressed at roughly equivalent levels,
thus ruling out the scenario that poor expression led to lack of
interaction (Fig. 3B, lower panel).
To determine the domain within the region 428–651 of
PMCA4b that interacts with calcineurin, a further series of
FLAG-tagged deletion mutants covering this region was gen-
erated, pF-PMCA4b-(428–575) and pF-PMCA4b-(428–500)
(Fig. 3C). The removal of amino acids 501–575 completely
prevented the interaction, as evidenced by the absence of co-
precipitated FLAG-PMCA4b-(428–500) with calcineurin (Fig.
3D). In summary, these results demonstrate that the region
501–575 of the catalytic large intracellular loop of PMCA4b is
necessary for the interaction with calcineurin.
PMCA4b Significantly Inhibits NFAT Transcriptional Activ-
ity—Previously reported interactions between calcineurin and
partner proteins have been shown to inhibit the activity of
calcineurin (25). We tested for a functional role of the PMCA-
calcineurin interaction as a modulator of calcineurin activity,
by assaying the effect of hPMCA4b expression on the transcrip-
tional activity of NFAT, one of the best characterized cal-
cineurin substrates.
HEK 293 cells were transfected with the NFAT-dependent
luciferase reporter vector pNFAT-TA-Luc (Clontech) and stim-
ulated with PMA and the calcium ionophore A23987 (Io) to
induce endogenous calcineurin activation and consequent
NFAT transcriptional activity. NFAT-dependent luciferase ac-
tivity was induced 8.5-fold in cells co-transfected with the
control vector pEGFP (Fig. 4A). However co-transfection with
pCMV-hPMCA4b, an expression plasmid encoding hPMCA4b,
significantly reduced (60% inhibition, p  0.05) PMA plus
Io-dependent activation of the luciferase reported vector (Fig.
4A). These results suggest that PMCA negatively regulates the
activity of endogenous calcineurin in mammalian cells.
To investigate the relevance of the interaction between the
two proteins and the inhibition of calcineurin activity, we
blocked the interaction by overexpressing an excess of the
region encompassing amino acids 428–651 of PMCA4b (Fig.
4B). Under these conditions ectopic PMCA4b was not able to
FIG. 4. PMCA4b significantly inhibits NFAT transcriptional
activity. A, PMCA4b inhibits the activation of an NFAT-dependent
luciferase reporter vector in response to PMA plus the calcium iono-
phore (Io) A23187. 4 g of pCMV-hPMCA4b (encoding hPMCA4b) or
control vector pEGFP, and 1 g of the NFAT-dependent luciferase
reporter vector pNFAT-TA-Luc (Clontech) were co-transfected in HEK
293 cells. Cells were stimulated with PMA (20 ng/ml) plus Io (1 M) for
16 h. Luciferase activity is expressed as -fold induction over the value of
the reporter vector in unstimulated cells. *, statistically significant (p
0.05, according to Student’s t test) 60% inhibition of the pNFAT-TA-Luc
reporter vector activity as a result of co-expression of human PMCA4b.
Means  S.E. of three independent experiments are shown. B, co-
expression of PMCA4b and the PMCA4b interaction domain (428–651)
reverses the inhibitory effect of PMCA4b. 3 g of the expression vector,
pCMV-hPMCA4b encoding hPMCA4b and 2 g of pFLAG-hPMCA4b-
(428–651) encoding hPMCA4b-(428–651), was co-transfected together
with 1 g of the NFAT-dependent luciferase reporter vector pNFAT-
TA-Luc in mammalian HEK 293 cells. Cells were stimulated with PMA
(20 ng/ml) plus Io (1 M) for 16 h. Luciferase activity is expressed as
-fold induction over the value of the reporter vector in unstimulated
cells. *, statistically significant (p  0.05, according to Student’s t test)
60% inhibition of the pNFAT-TA-Luc reporter vector activity as a result
of co-expression of human PMCA4b, which is reversed by the co-expres-
sion of pFLAG-hPMCA4b-(428–651).
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inhibit the activity of endogenous calcineurin, demonstrating
the functional significance of the interaction. These findings
were specific and not the result of generalized transcriptional
repression, because -galactosidase expression (encoded by
plasmid pEF-LacZ) was not influenced by co-expression of
hPMCA4b-(data not shown).
PMCA4b Is Unable to Inhibit a Calcium/Calmodulin-inde-
pendent Constitutively Active Mutant of Calcineurin A—We
next assessed the effect of PMCA on the activity of FLAG-
CnA-(2–389), a constitutively active mutant of calcineurin A
that is known to activate NFAT in a calcium/calmodulin-
independent manner.
HEK 293 cells were co-transfected with the NFAT-depend-
ent luciferase reporter vector pNFAT-TA-Luc (Clontech),
pFCnA-(2–389), an expression vector encoding FLAG-CnA-(2–
389), and either an expression vector encoding EGFP (control
plasmid) or an expression vector encoding hPMCA4b-(pCMV-
PMCA4b). The constitutively active calcineurin A mutant in-
creased NFAT-dependent luciferase activity around 6.5-fold in
the presence of the EGFP protein (Fig. 4B). Co-expression of
hPMCA4b, however, was not able to inhibit this constitutively
active calcineurin A mediated induction of NFAT-dependent
luciferase activity (Fig. 5).
PMCA4b Recruits Endogenous Calcineurin from the Cyto-
plasm to the Plasma Membrane—A negative modulatory effect
of PMCA4b on calcineurin via direct physical interaction re-
quires the localization of calcineurin in the plasma membrane.
Moreover, we would expect to observe an effect of PMCA4b on
the calcineurin distribution.
Western blot analysis of a 1:3 dilution of the total plasma
membrane-bound protein fraction and a 1:100 dilution of the
total cytoplasmic protein fraction revealed the presence of both
cytoplasmic and plasma membrane-associated calcineurin (Fig.
6A). When HEK 293 cells were transfected with an expression
vector encoding hPMCA4b (pCMV-PMCA4b), a reduced level of
cytoplasmic calcineurin and increased level of calcineurin in the
plasma membrane was observed. Transfection of an expression
vector encoding EGFP (control plasmid) did not affect calcineurin
distribution (Fig. 6, A and B). Quantification of plasma mem-
brane calcineurin by densitometry confirmed a 28% increase in
calcineurin localization at the plasma membrane fraction in the
presence of ectopic PMCA4b (Fig. 6B). Conversely, in the cyto-
plasmic fraction, a 38% reduction in calcineurin level was ob-
served in the pCMV-PMCA4b-transfected cells compared with
the pEGFP-transfected cells (Fig. 6B).
DISCUSSION
Through its effect on the NFAT family of transcription
factors, calcineurin represents a crucial mediator of cellular
function, differentiation, and adaptation (7). In this work we
describe a novel role for the plasma membrane Ca2/calmod-
ulin-ATPase pump, PMCA, as an inhibitor of calcineurin
signaling. Calcineurin A and PMCA interacted in mamma-
lian cells. PMCA bound equally well to full-length calcineurin
A and a constitutively active deletion mutant (Fig. 1, A and
B), and the interaction domain mapped to amino acids 58–
143 located within the catalytic domain of calcineurin A.
The interaction of PMCA4b with the catalytic subunit of
calcineurin A is similar to the interactions reported for other
calcineurin interaction partners (immunophilins, AKAP79,
cabin-1, MCIP1, or calsarcins) that also exert their inhibitory
effect by binding to the catalytic subunit (25, 29). Our results
suggest that interaction of PMCA does not require binding of
calcineurin B or Ca2/calmodulin to calcineurin A, which is
also true for modulatory calcineurin-interacting proteins
(MCIPs) (30). The interaction of PMCA with calcineurin A
occurs at a site distinct from the main immunophilin-immuno-
suppressant complex binding region (31, 32). Crystal structure
studies have demonstrated that cyclophilin A-CsA and
FKBP12-FK506 complexes bind to calcineurin residues within
a highly conserved region that overlaps with the binding do-
main for CnB (31). All the known endogenous modulators of
FIG. 5. PMCA4b is unable to inhibit the activation of an NFAT-dependent luciferase reporter vector in response to pFCnA-(2–389),
a constitutively active deletionmutant of calcineurin A. 3 g of a expression vector, pFCnA-(2–389), encoding a constitutively active deletion
mutant of calcineurin A or its corresponding empty vector, pEF-FLAG, was co-transfected together with 1.5 g of the expression vector
pCMV-hPMCA4b (encoding hPMCA4b), or control vector pEGFP-C1 (Clontech), and 1 g of the NFAT-dependent luciferase reporter vector
pNFAT-TA-Luc in mammalian HEK 293 cells. Cells were transfected for 24 h, washed with PBS, and incubated for 16 additional hours. Luciferase
activity is expressed as -fold induction over the value of the reporter vector in cells co-transfected with the empty vectors pEF-FLAG and
pEGFP-C1. Transfection efficiency was normalized by co-transfection of the pEF-LacZ plasmid as internal control and measure of -galactosidase
expression. Means  S.E. of three independent experiments are shown.
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calcineurin, with the exception of calsarcins, exert their effects
through interaction with calcineurin residues that overlap with
the immunophilin-binding sites (33). This is in contrast to the
PMCA binding domain, although AKAP79 has been reported to
bind to two regions of calcineurin (residues 30–98 and 311–
336), one of which partially overlaps with the identified PMCA-
binding site (32). PMCA4b is therefore likely to represent a
new, non-competitive inhibitor of calcineurin.
Transient expression of PMCA4b strongly reduced the re-
sponse of a NFAT-dependent luciferase reporter vector to stim-
ulation with PMA plus Io (Fig. 4A). This inhibition reflects the
effect of PMCA4b on endogenous calcineurin. We suggest that
this functional effect is facilitated by the recruitment of cal-
cineurin by PMCA4b to a cellular microenvironment where the
concentrations of Ca2 are kept low, which would thus reduce
the phosphatase activity of the enzyme. This interpretation is
corroborated by the reversal of inhibition observed when
PMCA4b is co-expressed with its interaction domain. Further-
more, the inability of PMCA4b to confer an inhibitory effect on
constitutively active calcineurin A suggests this functional in-
teraction is dependent on calcium/calmodulin.
The intracellular domain of PMCA responsible for the in-
teraction with calcineurin was mapped to the region contain-
ing amino acids 501–575, located within the catalytic intra-
cellular loop of PMCA4b between trans-membrane domains 4
and 5. Structurally, the region 501–575 of PMCA4b differs
from the interaction domains identified in the other endoge-
nous proteins that also inhibit calcineurin. AKAP79, Cain,
and MCIP, have been reported to contain a conserved motif
(PXIXIT) (25), which is also present in the NFAT proteins
(34). The presence of this motif in the inhibitory proteins
displaces NFAT binding to calcineurin, and subsequently
inhibits NFAT activation. An examination of the region 501–
575 of PMCA4b did not reveal any sequence resembling the
PXIXIT motif indicating an alternative mechanism to PX-
IXIT competition must be involved in PMCA-dependent
NFAT inhibition. The mechanism responsible for this inhibi-
tion is unclear at present. In fact, BLAST searches (basic
local alignment search tool) carried out with this sequence
did not show any significant homology to known proteins in
the data base except other PMCA isoforms. The high conser-
vation of this sequence in the other members of the PMCA
family of proteins (80% amino acid identity) suggests that
calcineurin A may also interact with other PMCA isoforms.
FIG. 6. PMCA4b recruits endoge-
nous calcineurin from the cytoplasm
to the plasma membrane. A, HEK 293
cells were transfected with an expression
vector encoding hPMCA4b (pCMV-
PMCA4b) or control vector pEGFP. A 1:3
dilution of the total plasma membrane-
bound proteins and a 1:100 dilution of the
total cytoplasmic fraction were analyzed
by Western blot, using an anti-calcineurin
monoclonal antibody (BD Bioscience), to
examine the effect of PMCA4b expression
on endogenous calcineurin localization.
Calcineurin is seen to be present in both
the plasma membrane and the cytoplas-
mic fractions. In the presence of ectopic
PMCA4b, there is a reduced level of cal-
cineurin in the cytoplasmic fraction and
an increased level of calcineurin in the
plasma membrane fraction compared
with the control pEGFP. B, quantification
of calcineurin localization by densitome-
try, expressed as percentage of cal-
cineurin levels in control pEGFP-trans-
fected cells. Increased calcineurin levels
in plasma membrane fractions and re-
duced calcineurin levels in the cytoplas-
mic fractions of cells as a result of co-
expression of human PMCA4b are
observed. Means of two independent ex-
periments are shown.
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This interaction is contingent upon sub-cellular localizations
that place calcineurin and PMCA together. There is precedence
for proposing localization of calcineurin to the plasma mem-
brane. Calcineurin has been implicated in -amino-3-hydroxy-
5-methyl-4-isoxazole propionic acid receptor dephosphoryl-
ation, and thus regulation at excitatory synapses (35), via a
signaling complex of three second messenger-regulated signal-
ing enzymes, including the calcineurin anchoring protein
AKAP79 (36, 37), which in turn interacts with SAP97, a PDZ
domain-containing protein known to interact with PMCA (38).
Our findings are consistent with this. Furthermore, the data
indicate a definite trend that goes one step further in suggest-
ing PMCA4b may be involved in the physical recruitment of
calcineurin from the cytoplasm to the plasma membrane where
the two proteins directly interact.
Both proteins are calcium/calmodulin-dependent, and PMCA
itself is a calcium-extruding pump. Proposing a calcium-de-
pendent mechanism is not only intuitive but supported by our
data. Although our work focuses on the effect of PMCA4b on
calcineurin, it may be that calcineurin interaction with the
PMCA catalytic domain modifies the Ca2 transporting activ-
ity of the protein. Elucidating the relationship between the
calcium-extruding role of PMCA4b and the recruitment of cal-
cineurin, as well as the actual physical interaction, is a complex
process and beyond the scope of this study. We are currently
investigating this in our laboratory.
The diverse physical interactions of PMCA with signal trans-
duction molecules such as calcineurin (this work), RASSF1
(24), neuronal nitric-oxide synthase (13), and CASK (14), thus
provide a substantial backdrop for its prevailing role as a
pivotal organizer of signal transduction complexes. Indeed, the
emergent role of PMCA can be characterized nicely when this
work is taken in context of our recent demonstration of a
functional interaction between PMCA and the tumor suppres-
sor protein RASSF1. This interaction leads to an inhibition of
the extracellular signal-regulated kinase (ERK) pathway (24).
ERK signaling activates the AP-1 transcription factor (39), and
NFAT interacts with AP-1 to form a cooperative composite
binding site in the promoter regions of many target genes (40).
Thus both the calcineurin and ERK pathways, which lead to
activation of transcription factors NFAT and AP-1, respec-
tively, appear to have a common denominator in PMCA as an
upstream regulator that inhibits these signaling pathways
(Fig. 7).
In summary, our results offer strong evidence for a novel
functional interaction between PMCA and calcineurin, sug-
gesting a role for PMCA as an organizer and negative modula-
tor of calcineurin-mediated signaling pathways in mammalian
cells. The implications of these findings are potentially far-
reaching, considering the ubiquitous nature of calcineurin and
its key role in diverse cellular processes. Further investigations
of this interaction with in vivo studies are necessary to enhance
our understanding of these findings at a physiological and
pathophysiological level.
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